Quantcast

Latest Janssen Pharmaceutica Stories

2014-10-18 23:01:41

The Firm is representing numerous Risperdal lawsuit plaintiffs in claims that allege the atypical antipsychotic medication caused gynecomastia, or male breast growth. New York, New York (PRWEB) October 18, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, 888 product liability claims have been filed in...

2014-10-15 12:31:56

NEW YORK, Oct. 15, 2014 /PRNewswire/ -- As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, a hearing recently held in Vermont is raising serious questions about the adherence to pediatric dosing guidelines by doctors who prescribe antipsychotic drugs like Risperdal to children, Bernstein Liebhard LLP reports. According to Dr. David C. Rettew, Director of the Pediatric Psychiatry Clinic at University of Vermont's College of Medicine, a...

2014-10-11 23:03:48

Risperdal Lawsuit Claims Continue With Meeting Scheduled In October For Gynecomastia Lawsuits Pending Litigation Columbus, OH (PRWEB) October 11, 2014 As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the...

2014-10-10 23:01:05

The Firm is representing numerous Risperdal lawsuit clients in the Pennsylvania litigation, all of whom allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) October 10, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the atypical antipsychotic medication caused men and boys to develop gynecomastia (male breast growth) continue to move forward in a mass tort litigation now...

2014-10-10 08:23:54

Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif., Oct. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the upcoming American Society of Anesthesiologists (ASA 2014) meeting October 11(th) to October 15(th), 2014 at the Ernest N. Morial Convention Center in New Orleans, LA. The annual...

2014-09-30 08:32:38

Acquisition Strengthens Existing Pipeline in Viral Diseases NEW BRUNSWICK, N.J., Sept. 30, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash. The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including...

2014-09-26 23:01:57

The Firm is representing numerous clients in Risperdal lawsuits that allege the use of the antipsychotic medication caused gynecomastia (male breast growth). New York, New York (PRWEB) September 26, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the use of the antipsychotic medication caused men and boys to develop gynecomastia (male breast growth) continue to move forward in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of...

2014-09-23 23:02:39

The Firm is representing numerous Risperdal lawsuit plaintiffs who allegedly suffered gynecomastia (male breast growth) due to their use of the antipsychotic medication. New York, New York (PRWEB) September 23, 2014 Risperdal lawsuits (http://www.drugbot.com/risperdal/lawsuit/) continue to move forward in courts around the country, Bernstein Liebhard LLP reports. According to an Order issued in U.S. District Court, Middle District of Florida on September 19th, the Court has dismissed...

2014-09-22 08:27:57

-Focus on Commercial Readiness and Global Operations- LEXINGTON, Mass., Sept. 22, 2014 /PRNewswire/ -- Synageva BioPharma Corp. ("Synageva") (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders announced today the appointment of Robert Bazemore as Chief Operating Officer. Reporting directly to Sanj K. Patel, President and Chief Executive Officer, Robert will oversee the planned global commercial launch of the company's lead program,...

2014-09-21 23:01:32

The Firm is representing numerous Risperdal lawsuit plaintiffs who have filed cases in Pennsylvania that allege the drug caused gynecomastia (male breast growth). New York, New York (PRWEB) September 21, 2014 Hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to move forward in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, the proceeding’s next monthly meeting has been scheduled for...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related